Letter
Medicine, General & Internal
Brendon G. Neuen, Robert Fletcher, Hiddo J. L. Heerspink
Summary: The editorial suggests that the benefit of empagliflozin in slowing the progression of chronic kidney disease is less evident among patients who do not receive RAS blockade. This is because this subgroup only accounts for 15% of the overall trial population, resulting in less precise effect estimates and wider confidence intervals.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Ashish Verma, Anand Vaidya, Sonu Subudhi, Sushrut S. Waikar
Summary: The study found that higher serum aldosterone levels are independently associated with an increased risk for kidney disease progression in individuals with chronic kidney disease, regardless of concomitant diabetes. This suggests a potential role for mineralocorticoid receptor antagonists in delaying CKD progression even in those without diabetes.
EUROPEAN HEART JOURNAL
(2022)
Review
Medicine, General & Internal
Kamyar Kalantar-Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic
Summary: Chronic kidney disease is a progressive disease with no cure, and preserving kidney function through lifestyle adjustments and pharmacological interventions can improve outcomes. A plant-dominant, low-protein, and low-salt diet may help mitigate glomerular hyperfiltration and preserve renal function. Various pharmacotherapies can also be used to alter intrarenal haemodynamics and protect the kidney from further damage.
Review
Chemistry, Multidisciplinary
Solmaz Maleki Dizaj, Aziz Eftekhari, Shakar Mammadova, Elham Ahmadian, Mohammadreza Ardalan, Soodabeh Davaran, Aygun Nasibova, Rovshan Khalilov, Mahbuba Valiyeva, Sevil Mehraliyeva, Ebrahim Mostafavi
Summary: This review focuses on current research and clinical applications of nanoparticles in the diagnosis of chronic kidney disease (CKD) and other renal diseases that may lead to CKD.
APPLIED SCIENCES-BASEL
(2021)
Article
Biochemistry & Molecular Biology
Huan-Da Chen, Chih-Chuan Yu, I-Hsiao Yang, Chi-Chih Hung, Mei-Chuan Kuo, Der-Cherng Tarng, Jer-Ming Chang, Daw-Yang Hwang
Summary: This study reveals the significance of ADTKD-UMOD as a cause of chronic kidney disease in the Taiwanese population, identifying two previously unreported UMOD missense variants.
Review
Biochemistry & Molecular Biology
Silvio Borrelli, Ida Matarazzo, Eugenio Lembo, Laura Peccarino, Claudia Annoiato, Maria Rosaria Scognamiglio, Andrea Foderini, Chiara Ruotolo, Aldo Franculli, Federica Capozzi, Pavlo Yavorskiy, Fatme Merheb, Michele Provenzano, Gaetano La Manna, Luca De Nicola, Roberto Minutolo, Carlo Garofalo
Summary: Increasing potassium intake can improve blood pressure and cardiovascular outcomes, but hyperkalaemia is prevalent in CKD patients and associated with poor prognosis. The correct nutritional approach to hyperkalaemia is still controversial, but new K+-binder drugs offer a safe and effective option for controlling serum potassium levels.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, Robert Damoiseaux, Susanne B. Nicholas
Summary: Osteopontin (OPN) is a protein with various physiological functions and has been implicated in the pathogenesis of chronic kidney disease (CKD). OPN may serve as a biomarker in CKD and targeting OPN could be a potential treatment strategy.
Review
Cardiac & Cardiovascular Systems
Ashton C. Lai, Solomon W. Bienstock, Raman Sharma, Karl Skorecki, Frans Beerkens, Rajeev Samtani, Andrew Coyle, Tonia Kim, Usman Baber, Anton Camaj, David Power, Valentin Fuster, Martin E. Goldman
Summary: Cardiovascular disease is the leading cause of death in end-stage renal disease patients, exacerbated by dialysis treatment. Multimodality imaging may offer additional prognostication and risk stratification for these patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Urology & Nephrology
Johannes Ruhe, Jennifer Nadal, Barbara Barthlein, Heike Meiselbach, Ulla T. Schultheiss, Fruzsina Kotsis, Helena Stockmann, Vera Krane, Claudia Sommerer, Ivonne Loeffler, Turgay Saritas, Jan T. Kielstein, Thomas Sitter, Markus P. Schneider, Matthias Schmid, Christoph Wanner, Kai-Uwe Eckardt, Gunter Wolf, Martin Busch
Summary: Diabetes mellitus (DM) and chronic kidney disease (CKD) are known risk factors for cardiovascular disease and mortality. This study found that DM significantly increased the risk of cardiovascular and non-cardiovascular death, major adverse cardiovascular events, and hospitalization for heart failure in patients with moderate to severe CKD. The increased risk was similar in patients with CKD caused by cardiovascular/metabolic diseases and those with genuine CKD. Patients with DM and CKD caused by cardiovascular/metabolic diseases were particularly susceptible to heart failure.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Pedro Caetano Pinto, Cindy Roennau, Martin Burchardt, Ingmar Wolff
Summary: Kidney cancer and chronic kidney disease have different clinical management strategies, but share closely related cellular and molecular mechanisms, both involving the kidney's response to hypoxia. Fibrosis is a common factor in deteriorating renal function in both conditions.
Article
Endocrinology & Metabolism
Joao Victor Salgado, Miguel Angelo Goes, Natalino Salgado Filho
Summary: The global nephrology community acknowledges the increasing burden of kidney disease and emphasizes on early diagnosis, understanding of disease progression, and development of new therapeutic interventions. FGF21 is considered a key regulator of lipid, glucose, and energy metabolism, as well as stress responses. While promising results have been shown with FGF21 analogs in metabolic disease, its exact role in kidney function remains poorly understood.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Review
Pharmacology & Pharmacy
Jonatan Barrera-Chimal, Frederic Jaisser, Hans-Joachim Anders
Summary: Chronic kidney disease is a major public health concern globally, with MR antagonists emerging as a potential therapeutic approach against various forms of kidney disease. Experimental and clinical studies have shown the protective effects of MRAs in reducing albuminuria and slowing disease progression. Recent evidence also suggests that MRAs can reduce hard kidney outcomes, particularly in CKD associated with type 2 diabetes, highlighting their potential benefit in maximizing organ protection through combination therapy.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Meng Yang, Chang-An Geng, Xinguang Liu, Min Guan
Summary: Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) share similar pathogenic mechanisms, with dysregulation of lipid metabolism playing a key role in their development and progression. Dyslipidemia and release of pro-inflammatory cytokines caused by NAFLD may play crucial roles in the pathological progression of CKD.
Review
Biochemistry & Molecular Biology
Anastasia Poznyak, Nikolay K. Sadykhov, Andrey G. Kartuesov, Evgeny E. Borisov, Vasily N. Sukhorukov, Alexander N. Orekhov
Summary: Atherosclerosis is the leading cause of cardiovascular disease worldwide, and it shares several risk factors with chronic kidney disease. Patients with chronic kidney disease are more susceptible to cardiovascular problems.
Review
Food Science & Technology
Puneet Agarwal, Vinita Garg, Priyanka Karagaiah, Jacek C. Szepietowski, Stephan Grabbe, Mohamad Goldust
Summary: The study focused on CKD-associated pruritus, the mechanism of which is not clear, and various treatments have been tried but with limited effectiveness.
Article
Transplantation
Lyuben Lyubenov, Chongxu Shi, Danyang Zhao, Luying Yang, Yutian Lei, Elmina Mammadova-Bach, Letizia de Chiara, Roberto Semeraro, Samuela Landini, Paola Romagnani, Elena Voerg, Satish K. Devarapu, Ricarda Welz, Stephan T. Kiessig, Hans-Joachim Anders
Summary: Cholesterol crystal (CC) embolism leads to acute kidney injury (AKI) and ischaemic cortical necrosis with high mortality. Injection of Glu-plasminogen (Glu-Plg) showed a dose-dependent attenuation of thrombotic angiopathy, GFR loss, and ischaemic necrosis in mice with CC embolism. Intermediate dose of Glu-Plg had transient protective effect, while high dose provided full protection without bleeding complications.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Medicine, General & Internal
Sankar D. Navaneethan, Sophia Zoungas, M. Luiza Caramori, Juliana C. N. Chan, Hiddo J. L. Heerspink, Clint Hurst, Adrian Liew, Erin D. Michos, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Jonathan C. Craig, David J. Tunnicliffe, Marcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing, Ian H. de Boer, Kamlesh Khunti
Summary: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline. The guideline was updated based on reviewing new evidence and using the GRADE approach to assess evidence and develop consensus practice points. The recommendations were updated in the areas of comprehensive care and glucose-lowering therapies, while recommendations in the areas of glycemic monitoring, lifestyle interventions, and management approaches remained unchanged.
ANNALS OF INTERNAL MEDICINE
(2023)
Review
Immunology
Erica Daina, Monica Cortinovis, Giuseppe Remuzzi
Summary: Dysregulation and accelerated activation of the alternative pathway of complement play important roles in kidney diseases, and complement-directed therapies have shown potential for treatment. Although there have been successful cases, incorporating these therapies into clinical practice still faces challenges.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Cardiac & Cardiovascular Systems
David J. T. Campbell, Marcello R. Tonelli, Brenda Hemmelgarn, Peter Faris, Jianguo Zhang, Flora T. Au, Ross Tsuyuki, Chad Mitchell, Raj Pannu, Tavis Campbell, Noah Ivers, Jane V. Fletcher, Derek J. Exner, Braden Manns
Summary: In a randomized trial conducted in Alberta, Canada, a tailored self-management education and support (SMES) program designed using advertising principles was found to reduce the rate of clinical outcomes among low-income older adults. The intervention included health promotion messaging and relay of clinical information to patients' healthcare providers. The study showed that the rate of the primary outcome, including death, myocardial infarction, stroke, coronary revascularization, and hospitalizations for cardiovascular-related conditions, was lower in the SMES group compared to the control group.
Review
Biochemistry & Molecular Biology
Carolina Conte, Giulia Antonelli, Maria Elena Melica, Mirko Tarocchi, Paola Romagnani, Anna Julie Peired
Summary: Chronic kidney disease (CKD) is a global health burden affecting over 840 million people worldwide. It presents sex disparities in its pathophysiology, epidemiology, clinical manifestations, and disease progression. While CKD is more frequent in females, males have a higher risk of progressing to end-stage kidney disease. Recent studies have highlighted the role of sex hormones in the development and progression of CKD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Public, Environmental & Occupational Health
Ahmad Hecham Alani, Laura Miller, Isaac Waweru, Aston B. Atwiine, Stella Njagi, Marcello Tonelli, Kelly Kisarach, Abdelrhman Mohammed, Ronald Mugera, Nazik Mohamed Ibrahim, Dina Abdulhammed Mohamad, Lilian Kiapi
Summary: Non-communicable diseases (NCDs) pose a significant global health challenge, especially in humanitarian contexts with limited healthcare resources. The WHO Non-Communicable Diseases Kit (WHO-NCDK) is an intervention aimed at primary healthcare facilities in emergency situations, providing essential medicines and equipment for NCD management. An operational evaluation in Sudan found that the kit played a critical role in ensuring continuity of care during disruptions in the supply chain. However, contextual factors such as community familiarity with healthcare facilities, integration of NCDs into primary healthcare, and monitoring and evaluation systems were identified as important considerations for enhancing the kit's utility.
Article
Endocrinology & Metabolism
Aneliya Parvanova, Manuela Abbate, Aina Maria Yanez, Miquel Bennasar-Veny, Angel Arturo Lopez-Gonzalez, Jose Ignacio Ramirez-Manent, Ilian Petrov Iliev, Sergio Fresneda, Maria Arias-Fernandez, Giuseppe Remuzzi, Piero Ruggenenti
Summary: This study investigated the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) in prediabetes, visceral obesity, and preserved kidney function, and explored the association between MAFLD and hyperfiltration. It was found that MAFLD was more frequent in hyperfiltering subjects and was independently associated with hyperfiltration, as well as potentiated the age-related decline in estimated glomerular filtration rate (eGFR).
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Biochemistry & Molecular Biology
Piera Trionfini, Elena Romano, Marco Varinelli, Lorena Longaretti, Paola Rizzo, Roberta Giampietro, Annalina Caroli, Sistiana Aiello, Marta Todeschini, Federica Casiraghi, Giuseppe Remuzzi, Ariela Benigni, Susanna Tomasoni
Summary: Induced pluripotent stem cells (iPSC) have the potential for cell therapy due to their self-renewal and differentiation capabilities. However, the high production costs and limited use for acute conditions hinder their applications. An allogeneic iPSC-based strategy may overcome these issues, but immune rejection is a concern. In this study, CRISPR/Cas9 was used to create hypoimmunogenic iPSCs that can differentiate into liver cells, providing a cost-effective and off-the-shelf opportunity for liver disease cell therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Urology & Nephrology
Norberto Perico, Giuseppe Remuzzi, Matthew D. Griffin, Paul Cockwell, Alexander P. Maxwell, Federica Casiraghi, Nadia Rubis, Tobia Peracchi, Alessandro Villa, Marta Todeschini, Fabiola Carrara, Bernadette A. Magee, Piero L. Ruggenenti, Stefano Rota, Laura Cappelletti, Veronica Mcinerney, Tomas P. Griffin, Md Nahidul Islam, Martino Introna, Olga Pedrini, Josee Golay, Andrew A. Finnerty, Jon Smythe, Willem E. Fibbe, Stephen J. Elliman, Timothy O'Brien, NEPHSTROM Trial Consortium
Summary: The NEPHSTROM study evaluates the safety, tolerability, and preliminary efficacy of ORBCEL-M cell therapy in adults with type 2 diabetes and progressive diabetic kidney disease. The results show that ORBCEL-M cell therapy is safe and well-tolerated in the lowest dose cohort, and significantly reduces the decline rate of eGFR over 18 months.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Urology & Nephrology
Zhihui Zhu, Karoline A. T. Rosenkranz, Yoshihiro Kusunoki, Chenyu Li, Martin Klaus, Oliver Gross, Maria-Lucia Angelotti, Giulia Antonelli, Luigi Cirillo, Paola Romagnani, Nassim Bouteldja, Alireza Vafaei Sadr, Roman D. Buelow, Peter Boor, Hans-Joachim Anders
Summary: A preclinical study in mice suggests that triple blockade of RAS/SGLT2/MR may significantly improve renal outcomes in Alport syndrome and other progressive CKDs due to synergistic effects on the glomerular and tubulointerstitial compartments.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Review
Urology & Nephrology
Tyrone G. Harrison, Marcello Tonelli
Summary: The measurement of proteinuria is crucial for diagnosing and monitoring kidney disease, but there is still controversy and uncertainty surrounding the optimal measurement method. International guidelines recommend the use of urinary albumin-to-creatinine ratio, but this method is not universally available and can be costly. Additionally, the accuracy of different measurement methods may vary depending on the magnitude of albuminuria, sex, and clinical contexts.
KIDNEY INTERNATIONAL
(2023)
Review
Urology & Nephrology
Mehmet Sukru Sever, Valerie Luyckx, Marcello Tonelli, Rumeyza Kazancioglu, Darlene Rodgers, Dani Gallego, Serhan Tuglular, Raymond Vanholder
Summary: Patients with kidney disease are more vulnerable to the adverse effects of disasters due to their reliance on infrastructure, technology, drugs, and medical personnel. Pre-disaster preparedness, training, and emergency responses can help mitigate risks and improve outcomes for these patients.
NATURE REVIEWS NEPHROLOGY
(2023)
Article
Medicine, General & Internal
Damiano Baldassarre, Licia Iacoviello, Roberta Baetta, Maria Carla Roncaglioni, Gianluigi Condorelli, Giuseppe Remuzzi, Gianfranco Gensini, Luigi Frati, Walter Ricciardi, Pier Giulio Conaldi, Antonio Uccelli, Fabio Blandini, Silvano Bosari, Giovanni Scambia, Massimo Fini, Antonio Di Malta, Mauro Amato, Fabrizio Veglia, Alice Bonomi, Catherine Klersy, Francesca Colazzo, Martino Pengo, Francesca Gorini, Luciana Auteri, Giuseppe Ferrante, Marta Baviera, Giuseppe Ambrosio, Alberico Catapano, Alessandro Gialluisi, Alexis Elias Malavazos, Serenella Castelvecchio, Massimiliano Marco Corsi-Romanelli, Rosanna Cardani, Maria Teresa La Rovere, Valentina Agnese, Bianca Pane, Daniele Prati, Laura Spinardi, Giovanna Liuzzo, Eloisa Arbustini, Maurizio Volterrani, Marco Visconti, Jose Pablo Werba, Stefano Genovese, Grzegorz Bilo, Cecilia Invitti, Anna Di Blasio, Carolina Lombardi, Andrea Faini, Debora Rosa, Luisa Ojeda-Fernandez, Andreana Foresta, Amalia De Curtis, Augusto Di Castelnuovo, Simonetta Scalvini, Antonia Pierobon, Alessandra Gorini, Luca Valenti, Livio Luzi, Annarosa Racca, Manuela Bandi, Elena Tremoli, Lorenzo Menicanti, Gianfranco Parati, Giulio Pompilio
Summary: The CV-PREVITAL study is a multicentre, prospective, randomised, controlled, open-label interventional trial aiming to compare the effectiveness of an educational and motivational mobile health intervention with usual care in reducing cardiovascular risk. The trial plans to enrol approximately 80,000 subjects without overt cardiovascular diseases and evaluate the short-term endpoints, as well as conduct a long-term follow-up to assess the incidence of major adverse cardiovascular events.
Review
Urology & Nephrology
Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi, Edouard L. Fu, Vianda S. Stel, Friedo W. Dekker, Kitty J. Jager
Summary: The 'legacy effect' describes the long-term benefits of intensive therapy in reducing complications and mortality in chronic diseases. It is evident in studies related to chronic kidney disease (CKD) and highlights the importance of intensive treatment. However, the legacy effect is more pronounced in early-stage diabetes and less evident in long-term, established diabetes patients.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Monica Locatelli, Daniela Rottoli, Rayan Mahmoud, Mauro Abbate, Daniela Corna, Domenico Cerullo, Susanna Tomasoni, Giuseppe Remuzzi, Carlamaria Zoja, Ariela Benigni, Daniela Macconi
Summary: In BTBR ob/ob mice with type 2 diabetic nephropathy, peritubular capillaries show endothelial cell abnormalities and basement membrane thickening. Remodeling and focal loss of the endothelial glycocalyx were observed in diabetic kidneys, and ACEi treatment preserved the glycocalyx and attenuated the ultrastructural abnormalities of peritubular capillaries.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)